Left Ventricular Infarct Size Assessed With 0.1 mmol/kg of Gadobenate Dimeglumine Correlates With That Assessed With 0.2 mmol/kg of Gadopentetate Dimeglumine

Abstract

Objective To determine myocardial infarct (MI) size during cardiovascular magnetic resonance (CMR) at 1.5 Tesla using 0.1 mmol/kg bodyweight of gadobenate dimeglumine (Gd-BOPTA) and 0.2 mmol/kg bodyweight of gadopentetate dimeglumine (Gd-DTPA). Methods Twenty participants (16 men, 4 women), aged 58 ± 12 years, with a prior chronic MI were imaged in a cross-over design. Participants received 0.2 mmol/kg bodyweight of Gd-DTPA, and 0.1 mmol/kg bodyweight of Gd-BOPTA on 2 occasions separated by 3 to 7 days Results The correlations were high between Gd-DTPA and Gd-BOPTA measures of infarct volume (r=0.93) and the percentage of infarct relative to LV myocardial volume (r=0.85). The size and location of the infarcts were similar (p=0.9) for the 2 contrast agents. Interobserver correlation of infarct volume (r=0.91) was high. Conclusions In chronic myocardial infarction, late gadolinium enhancement identified with a single 0.1 mmol/kg bodyweight dose of Gd-BOPTA is associated in volume and location to a double (0.2 mmol/kg body weight) dose of Gd-DTPA. Lower doses of higher relaxivity contrast agents should be considered for determining LV myocardial infarct size.

Enhancement in a brain glioma model: A comparison of half‐dose gadobenate dimeglumine versus full‐dose gadopentetate dimeglumine at 1.5 and 3 T

“…Previous studies in humans by Huang et al have demonstrated the feasibility of half‐dose imaging using gadobenate dimeglumine at 3 T vs. gadopentetate dimeglumine at 1.5 T in the setting of brain neoplasia . Analogous findings have been demonstrated in other applications . The present study further examines the ability to reduce gadolinium chelate dosage with gadobenate dimeglumine, hypothesizing that the near double r1 relaxivity of gadobenate dimeglumine at both 1.5 and 3 T relative to gadopentetate dimeglumine could allow for a halving of doses with the former while preserving lesion enhancement.…”

T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA

“…[3,7] Due to a higher relaxivity [13] related to protein binding, some publications report gadobenate dimeglumine (Gd-BOPTA) at a lower dose of 0.1 mmol/kg for CMR [14,15]. …”

Ultra low-dose of gadobenate dimeglumine for late gadolinium enhancement (LGE) imaging in acute myocardial infarction: A feasibility study

“…As previously reported by other authors [15][16][17][18]20], a gadobenate dimeglumine dose of 0.1 mmol/kg BW generally provides an excellent image quality for determinations of IM size and volume.…”

“…Comparative CMR studies, both inter-individually [15,16] and intra-individually [17,18], have similarly shown that a dose of 0.1 mmol/kg BW Gd-BOPTA is equivalent to a double 0.2 mmol/kg BW dose of Gd-DTPA in terms of both scar depiction and quantification of necrotic tissue.…”